Not Yet RecruitingNot Applicable

Analysis of the Efficacy and Stability of a Wearable ECG Monitor

100 participantsStarted 2024-09-09

Plain-language summary

This study aims to analyze the efficacy and safety of wearable electrocardiogram (ECG) monitoring by simultaneously attaching a single-channel patch-type wearable ECG monitoring device (HiCardi+ by Mezoo Co., Ltd.) and a telemetry device (IntelliVue MX40 by Philips) used in actual wards to patients prescribed with ECG monitoring

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adults aged 19 years or older
✓. Patients admitted to Chonnam National University Hospital who require ECG monitoring
✓. Individuals who have expressed their intention to participate in this study or have obtained written consent from a proxy

Exclusion criteria

✕. Individuals who are unable to provide consent themselves or through a legally designated representative
✕. Individuals deemed unsuitable for participation in the clinical trial based on the researcher's judgment

What they're measuring

The number of total QRS complex

Timeframe: Within 3 months after electrocardiogram monitoring procedure

The rate of signal loss

Timeframe: Within 3 months after electrocardiogram monitoring procedure

Trial details

NCT IDNCT06546046

SponsorMezoo Co., Ltd.

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12-30

Contact for this trial

SH Lee

82-33-761-2006 shlee@me-zoo.com

View on ClinicalTrials.gov More Arrhythmias, Cardiac trials